Regulation & Compliance

The SBA's new scorecard boasts a record $179B for small businesses, but a deep dive reveals a dramatic overhaul of equity programs in favor of a new merit-based model.

Canada's top medical body is backing a sweeping new law to protect kids online, shifting the debate from parental controls to platform accountability.

A new law targets the surge in copper theft, but its sweeping changes to bail and sentencing have critics warning of unintended consequences for the justice system.

Ottawa is rewriting its asylum playbook with new rules aimed at speed and efficiency. But as claim numbers plummet, critics warn the drive may erect new barriers for the world's most vulnerable.

AIXAlpha promises to make volatile crypto markets accessible to all. But as automation replaces experience, are investors gaining an edge or just new risks?

Canada's sweeping 'Protecting Victims Act' restores mandatory minimums and targets online predators, but new ISP rules ignite a fierce debate on privacy.

Digital health innovator Light AI has secured C$5M to navigate the regulatory maze. Can its AI platform truly revolutionize diagnostics from our pockets?

As Indonesia digitizes its judiciary to boost efficiency and global standing, a top court official warns that technology alone is not enough to deliver justice.

A new guide reveals the steep costs of Alexandria remodels, exposing a market shaped by historic homes, complex rules, and a strained labor force.

A major partnership in Michigan and Ohio's ENT sector signals a growing trend: private equity-backed groups are reshaping independent medical practices.

AKA Foods just launched a free, professional-grade food labelling tool, a strategic move to democratize compliance and funnel users to its core AI platform.

Belgravia Hartford's Gravitio AI boasts impressive prediction stats, but unverified metrics and a precarious financial backdrop reveal a high-stakes gamble.

As AI-driven attacks loom over critical infrastructure, IBM is arming its legacy Z mainframes with a new suite of AI-powered defensive tools.

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

With a new strategic funding round, LUMIQ aims to scale its autonomous AI, which makes auditable decisions in minutes, not weeks, for banks and insurers.

A strategic pharma alliance scores a major win in Japan's lucrative neurology market, signaling a new competitive front and hope for thousands of patients.

IIFL Capital's new Algo Marketplace offers 100+ automated strategies, tapping into India's retail investor boom. But does it truly democratize trading?

A prestigious award for its ASD therapy Speragen puts Korean biotech Astrogen in the spotlight. Now, the firm faces the gauntlet of regulatory approval and market entry.

Weeks after its acquisition by Goldman Sachs, Innovator is shuttering two ETFs. This move reveals the banking giant's plan to sharpen focus on core products.

A $4.6M lawsuit against Drake’s October’s Very Own reveals more than a financial dispute; it exposes the complex reality of celebrity brand valuation.